Nine More Firms Joined Medicaid Drug Discount Plan
The expansion brings 26 major pharmaceutical companies into a program aiming to align domestic prices with global benchmarks.
Updated on Oct. 4, 2026 in Healthcare
Live Poll
Do you believe government-negotiated drug pricing deals will effectively lower your healthcare costs?
President Trump signed agreements with nine additional pharmaceutical firms to offer discounted medications to state Medicaid programs across the United States. These new participants join 17 previously enrolled companies, bringing the total industry footprint to 26 firms.
Why it matters
The policy shift seeks to lower U.S. drug prices to levels comparable with those in other developed nations, ultimately aiming to reduce national healthcare costs. The program now encompasses firms representing 90% of the domestic pharmaceutical market.
The 26 total companies now participating in the program represent 90% of the domestic pharmaceutical market. The expansion is projected to generate more than $600 billion in total savings for Americans.
The players
President Trump
The President of the United States who oversees federal healthcare policy and executive agency enforcement.
Teva Pharmaceuticals
A global leader in generic and specialty medicines with a significant presence in the U.S. healthcare supply chain.
The details
The participating companies have committed to providing access to their drug portfolios for every state Medicaid program in the country. This effort supplements the TrumpRx website, launched by the administration in February, which facilitates direct-to-consumer access to discounted medications. These agreements function as part of a most-favored-nation policy designed to standardize pricing against international indices.
Timeline
February 2026: The administration launched the TrumpRx website.
October 4, 2026: President Trump announced the agreements with nine additional firms.
Market Landscape
This move marks a significant expansion of the federal government's most-favored-nation policy framework regarding prescription drug pricing. It follows the pattern of using direct administrative agreements to alter industry pricing structures without waiting for legislative action.
Operators in the healthcare sector should monitor whether these discounted drug rates impact regional reimbursement levels or state-level Medicaid formulary requirements. Business leaders with heavy ties to pharmacy benefit management should track the TrumpRx portal for shifts in consumer-direct pricing dynamics.
The takeaway
The consolidation of 90% of the domestic market under these discount agreements signals a more aggressive federal approach to drug cost management. Operators should re-evaluate their current pharmacy supply contracts against the pricing benchmarks emerging from these new manufacturer agreements.
Further reading
For broader context on federal drug pricing initiatives, visit the Healthcare section.
Source note: This article includes information reported by Hottalkradio.
Live Poll
Do you believe government-negotiated drug pricing deals will effectively lower your healthcare costs?
